Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 11
2016 8
2017 5
2018 7
2019 3
2020 3
2021 3
2022 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Automated Prediction of the Response to Neoadjuvant Chemoradiotherapy in Patients Affected by Rectal Cancer.
Filitto G, Coppola F, Curti N, Giampieri E, Dall'Olio D, Merlotti A, Cattabriga A, Cocozza MA, Taninokuchi Tomassoni M, Remondini D, Pierotti L, Strigari L, Cuicchi D, Guido A, Rihawi K, D'Errico A, Di Fabio F, Poggioli G, Morganti AG, Ricciardiello L, Golfieri R, Castellani G. Filitto G, et al. Among authors: rihawi k. Cancers (Basel). 2022 Apr 29;14(9):2231. doi: 10.3390/cancers14092231. Cancers (Basel). 2022. PMID: 35565360 Free PMC article.
The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer.
Mazzeschi M, Sgarzi M, Romaniello D, Gelfo V, Cavallo C, Ambrosi F, Morselli A, Miano C, Laprovitera N, Girone C, Ferracin M, Santi S, Rihawi K, Ardizzoni A, Fiorentino M, D'Uva G, Győrffy B, Palmer R, Lauriola M. Mazzeschi M, et al. Among authors: rihawi k. J Exp Clin Cancer Res. 2022 Mar 29;41(1):113. doi: 10.1186/s13046-022-02309-1. J Exp Clin Cancer Res. 2022. PMID: 35351152 Free PMC article.
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.
Andrini E, Lamberti G, Mazzoni F, Riccardi F, Bonetti A, Follador A, Artioli F, Genova C, Barbieri F, Frassoldati A, Brighenti M, Colantonio I, Pasello G, Ficorella C, Cinieri S, Tiseo M, Gelsomino F, Tognetto M, Rihawi K, Ardizzoni A. Andrini E, et al. Among authors: rihawi k. Future Oncol. 2022 Mar;18(7):771-779. doi: 10.2217/fon-2021-1027. Epub 2022 Jan 24. Future Oncol. 2022. PMID: 35068173
Expected and non-expected immune-related adverse events detectable by CT.
Ciccarese F, Piccinino A, Brocchi S, Balacchi C, Dall'Olio FG, Massari F, Rihawi K, Paccapelo A, Ardizzoni A, Golfieri R. Ciccarese F, et al. Among authors: rihawi k. Eur J Radiol. 2021 May;138:109617. doi: 10.1016/j.ejrad.2021.109617. Epub 2021 Feb 25. Eur J Radiol. 2021. PMID: 33676358
Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study.
Ricci C, Capizzi E, Giunchi F, Casolari L, Gelsomino F, Rihawi K, Natali F, Livi V, Trisolini R, Fiorentino M, Ardizzoni A. Ricci C, et al. Among authors: rihawi k. Ther Adv Med Oncol. 2020 Nov 30;12:1758835920954802. doi: 10.1177/1758835920954802. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33299472 Free PMC article.
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours.
de Bono J, Lin CC, Chen LT, Corral J, Michalarea V, Rihawi K, Ong M, Lee JH, Hsu CH, Yang JC, Shiah HS, Yen CJ, Anthoney A, Jove M, Buschke S, Fuertig R, Schmid U, Goeldner RG, Strelkowa N, Huang DC, Bogenrieder T, Twelves C, Cheng AL. de Bono J, et al. Among authors: rihawi k. Br J Cancer. 2020 Apr;122(9):1324-1332. doi: 10.1038/s41416-020-0774-1. Epub 2020 Mar 12. Br J Cancer. 2020. PMID: 32161368 Free PMC article. Clinical Trial.
41 results